New updates on hepatopulmonary syndrome: A comprehensive review

Respir Med. 2025 Jan:236:107911. doi: 10.1016/j.rmed.2024.107911. Epub 2024 Dec 9.

Abstract

Hepatopulmonary syndrome (HPS) is a serious pulmonary vascular complication that causes arterial hypoxemia in the setting of liver disease. HPS has a progressive course and is associated with a two-fold increased risk of mortality relative to cirrhotic patients without HPS. It primarily affects patients with portal hypertension. The key pathological features of HPS include intrapulmonary angiogenesis and vascular dilations (IPVDs). The prevalence of HPS varies widely due to inconsistent diagnostic criteria and a lack of standardized protocols. Despite advances in understanding its pathophysiology, no effective curative treatments for HPS exist. Liver transplantation remains the only definitive treatment, improving survival and altering the disease natural course. This review explores the pathophysiology, clinical features, and therapeutic strategies for HPS, highlighting recent advances in the literature.

Keywords: Common bile duct ligation; Hepatopulmonary syndrome; Liver transplantation; Monocyte recruitment; Nitric oxide; Vascular endothelial growth factor.

Publication types

  • Review

MeSH terms

  • Disease Progression
  • Hepatopulmonary Syndrome* / diagnosis
  • Hepatopulmonary Syndrome* / etiology
  • Hepatopulmonary Syndrome* / physiopathology
  • Hepatopulmonary Syndrome* / therapy
  • Humans
  • Hypertension, Portal / diagnosis
  • Hypertension, Portal / etiology
  • Hypertension, Portal / physiopathology
  • Hypertension, Portal / therapy
  • Hypoxia / physiopathology
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / physiopathology
  • Liver Transplantation*
  • Prevalence